Free Trial

Envista (NVST) Stock Forecast & Price Target

Envista logo
$21.15 +0.78 (+3.83%)
(As of 11:50 AM ET)

Envista - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
11
Buy
3

Based on 15 Wall Street analysts who have issued ratings for Envista in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 1 has given a sell rating, 11 have given a hold rating, and 3 have given a buy rating for NVST.

Consensus Price Target

$20.71
-2.09% Downside
According to the 15 analysts' twelve-month price targets for Envista, the average price target is $20.71. The highest price target for NVST is $26.00, while the lowest price target for NVST is $16.00. The average price target represents a forecasted downside of -2.09% from the current price of $21.15.
Get the Latest News and Ratings for NVST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Envista and its competitors.

Sign Up

NVST Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
11 Hold rating(s)
9 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.71$19.63$19.14$34.63
Forecasted Upside-2.09% Downside5.17% Upside2.33% Upside44.42% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

NVST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Envista Stock vs. The Competition

TypeEnvistaMedical CompaniesS&P 500
Consensus Rating Score
2.13
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-2.09% Downside27,212.41% Upside8.86% Upside
News Sentiment Rating
Positive News

See Recent NVST News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2024Leerink Partnrs
5 of 5 stars
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
10/31/2024Piper Sandler
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$16.00 ➝ $17.00-19.96%
10/31/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingHold
10/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$17.00 ➝ $22.00+14.58%
10/31/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$16.00 ➝ $23.00+19.79%
10/23/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$18.00 ➝ $21.00+12.90%
Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

10/8/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Chopra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$20.00+9.59%
9/23/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$18.00 ➝ $23.00+18.92%
8/8/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$22.00 ➝ $19.00+16.78%
8/8/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$23.00 ➝ $16.00+4.58%
5/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell ➝ Sell$20.00 ➝ $17.50-8.71%
4/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$33.00 ➝ $21.00+4.90%
2/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$30.00 ➝ $23.00+2.54%
2/8/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Vazquez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
1/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$26.00+11.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:15 PM ET.


NVST Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Envista is $20.71, with a high forecast of $26.00 and a low forecast of $16.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Envista in the last twelve months. There is currently 1 sell rating, 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVST, but not buy additional shares or sell existing shares.

According to analysts, Envista's stock has a predicted downside of -2.09% based on their 12-month stock forecasts.

Over the previous 90 days, Envista's stock had 2 upgrades by analysts.

Envista has been rated by research analysts at Evercore ISI, Leerink Partners, Leerink Partnrs, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Analysts like Envista less than other "medical" companies. The consensus rating for Envista is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVST compares to other companies.


This page (NYSE:NVST) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners